曲克芦丁:一种具有心血管保护作用的新型腹膜透析渗透剂
本研究在体外、小鼠及人腹膜间皮细胞中评估曲克芦丁作为腹膜透析渗透剂的效果。结果显示曲克芦丁渗透与超滤能力与葡萄糖相似,但不降低间皮细胞活力、不诱导间皮-间质转化;在5/6肾切除小鼠中,长期使用葡萄糖透析液增加腹膜增厚、炎症标志物和心血管损伤,而曲克芦丁透析液未引起这些不良效应。
要点
- 曲克芦丁渗透和超滤能力与葡萄糖相似,且具有胶体特性。
- 曲克芦丁不降低间皮细胞活力,不诱导间皮-间质转化。
- 在肾功能不全小鼠中,曲克芦丁透析液未引起腹膜增厚和心血管损伤。
核心结论
- 曲克芦丁是比葡萄糖更具生物相容性的腹膜透析渗透剂,在临床前研究中无 adverse 局部或全身副作用。
研究设计与样本
- 体外实验使用人工膜和人腹膜间皮细胞,体内实验使用小鼠。
- 临床前模型为5/6肾切除C57BL/6J小鼠,每日暴露于葡萄糖或曲克芦丁腹膜透析液60天。
主要发现
- 曲克芦丁在体外和体内均表现出与葡萄糖相似的渗透和超滤能力,但具有胶体特性。
- 仅葡萄糖降低间皮细胞活力、诱导间皮-间质转化并增加损伤标志物(如白细胞介素-6和血管内皮生长因子A)。
- 长期葡萄糖透析液显著增加小鼠腹膜增厚、组织促炎标志物(腹膜、肾脏、心脏和主动脉)及心血管损伤(心脏肥大和纤维化),曲克芦丁透析液未引起这些效应。
临床怎么用
- 曲克芦丁有望作为葡萄糖的替代渗透剂,减少腹膜透析相关心血管并发症。
局限性
- 研究仅为临床前实验,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: End-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and increased cardiovascular pathology. These complications can be exacerbated by exposure to PD solutions (PDS) containing glucose. This highlights the clinical unmet need for novel osmotic agents to replace glucose. Here, we tested troxerutin, a Food and Drug Administration-approved drug, as a potential osmotic agent. METHODS: To evaluate troxerutin osmotic and non-toxic effects, in vitro and in vivo experiments were carried out using artificial membranes, mice and cultured human mesothelial cells (MCs). The local and systemic consequences of chronic peritoneal exposure to PDS associated to renal insufficiency were investigated in a preclinical model. 5/6 nephrectomized C57BL/6J mice were daily exposed to glucose- or troxerutin-PDS for 60 days, then evaluating tissue damage, proinflammatory markers and cardiac damage. RESULTS: In vitro and in vivo studies revealed that troxerutin exhibits similar osmotic and ultrafiltration capacities to glucose, but with colloidal properties. Moreover, only glucose, but not troxerutin, reduced MC viability, induced mesothelial-to-mesenchymal transition, and increased damage markers (such as interleukin-6 and vascular endothelial growth factor A). In the preclinical model, long-term treatment with glucose-PDS, but not troxerutin-PDS, significantly increased peritoneal membrane thickening, tissue proinflammatory markers (evaluated in peritoneum, kidney, heart and aorta) and cardiovascular damage (cardiac hypertrophy and fibrosis) in mice. These preclinical data clearly demonstrate the wide deleterious effects of chronic peritoneal exposure to glucose-containing PDS in mice with kidney insufficiency and that the replacement of glucose with troxerutin notably reduces these effects. CONCLUSION: Troxerutin emerges as a more biocompatible alternative to glucose as an osmotic agent for PD therapy, exhibiting no adverse local or systemic side effects in preclinical studies. This research presents a novel approach to reduce cardiovascular complications of PD in end-stage kidney disease.
引用
- Kopytina V, Marchant V, Rodrigues-Diez R, et al. Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions. Nephrol Dial Transplant. 2026. PMID: 41231614. doi:10.1093/ndt/gfaf249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。